Institutional members access full text with Ovid®

Share this article on:

New and emerging therapies in treatment of Clostridium difficile infection

Goyal, Hemanta; Perisetti, Abhilashc; Rehman, M., Rubayatc; Singla, Umeshb

European Journal of Gastroenterology & Hepatology: June 2018 - Volume 30 - Issue 6 - p 589–597
doi: 10.1097/MEG.0000000000001103
Review Article

Clostridium difficile infection (CDI) represents one of the most serious nosocomial infections that have grown dramatically over the past decade. Vancomycin and metronidazole are currently used as a standard therapy for CDI. Metronidazole is recommended as a first-line therapy for mild-to-moderate infections and vancomycin is mainly used for severe and/or refractory cases. However, studies have demonstrated that there are quite high CDI relapse rates with both of these medications, which represents a challenge for clinicians. Over the last decade, a number of newer and novel therapeutic options have emerged as promising alternatives to these standard CDI therapies. The following review provides the updated summaries of these newer therapeutic agents and their status in the treatment of CDI.

aDepartment of Internal Medicine, Mercer University School of Medicine

bDepartment of Internal Medicine, Medical Center Navicent Health, Macon, Georgia

cDepartment of Family and Community Medicine, Texas Tech University, Lubbock, Texas, USA

Correspondence to Hemant Goyal, MD, FACP, Mercer University School of Medicine, 707 Pine Street, Macon, GA 31201, USA Tel: +1 478 301 5862; fax: +1 478 301 5841; e-mail: doc.hemant@yahoo.com

Received November 26, 2017

Accepted January 30, 2018

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.